ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 170 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $60 | -25.9% | 4,658 | 0.0% | 0.00% | – |
| Q1 2024 | $81 | +84.1% | 4,658 | 0.0% | 0.00% | – |
| Q4 2023 | $44 | -99.5% | 4,658 | -95.0% | 0.00% | -100.0% |
| Q3 2023 | $8,514 | +8414.0% | 92,283 | +1881.2% | 0.02% | – |
| Q2 2023 | $100 | -46.8% | 4,658 | 0.0% | 0.00% | -100.0% |
| Q1 2023 | $188 | -13.4% | 4,658 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $217 | -99.9% | 4,658 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $242,000 | +10.0% | 4,658 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $220,000 | -33.7% | 4,658 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $332,000 | -55.3% | 4,658 | -53.0% | 0.00% | -33.3% |
| Q4 2021 | $742,000 | +9.0% | 9,919 | -17.2% | 0.00% | 0.0% |
| Q3 2021 | $681,000 | +29.2% | 11,982 | 0.0% | 0.00% | +50.0% |
| Q2 2021 | $527,000 | -65.4% | 11,982 | -71.5% | 0.00% | -84.6% |
| Q3 2015 | $1,521,000 | -12.0% | 42,100 | +9.6% | 0.01% | -7.1% |
| Q2 2015 | $1,728,000 | +46.9% | 38,400 | 0.0% | 0.01% | +40.0% |
| Q1 2015 | $1,176,000 | – | 38,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,599,109 | $63,277,000 | 8.68% |
| SENZAR ASSET MANAGEMENT, LLC | 566,903 | $22,432,000 | 6.58% |
| Sarissa Capital Management LP | 105,000 | $4,155,000 | 1.60% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 136,637 | $5,407,000 | 1.41% |
| RA Capital Management | 250,000 | $9,893,000 | 1.17% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 110,515 | $4,373,000 | 0.99% |
| Ghost Tree Capital, LLC | 35,000 | $1,385,000 | 0.75% |
| WALL STREET ASSOCIATES | 159,100 | $6,296,000 | 0.65% |
| BAILARD, INC. | 91,500 | $3,621,000 | 0.56% |
| EAM Investors, LLC | 62,768 | $2,484,000 | 0.50% |